“…High expression of human epidermal growth factor receptor 2 (HER2) in breast and gastroesophageal carcinomas is a predictive biomarker for treatment using HER2-targeted therapeutics (antibodies trastuzumab and pertuzumab, antibody-drug conjugate trastuzumab DM1, and tyrosine kinase inhibitor lapatinib). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The interaction between ER-α36 and EGFR/HER-2 were detected using CoIP. A mouse xenograft model of breast cancer was established to verify the role of ER-α36 in vivo. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…MATERIALS AND METHODS: In this study, HER-2 peptide-PEG(2000)-Schiff base-cholesterol (HPSC) derivate was synthesized successfully and incorporated it on the surface of the doxorubicin (DOX)-loaded dequalinium (DQA) chloride vesicle (HPS-DQAsomes) to treat drug-resistant breast cancer. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…HER2-positive breast cancer correlates with more aggressive tumor growth, a poorer prognosis and reduced overall survival. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…MATERIAL AND METHODS: This retrospective study included women with HER2-positive BCs (stage I–III) treated with trastuzumab from 2008 to 2017. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We explored the combination of data-mining and a large claims database to estimate the direct healthcare costs of HER2-positive breast cancer (BC) treatment in Iran and the fraction of total costs from trastuzumab use. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We additionally show that ERAS synergistically enhances HER2-induced tumorigenesis and, in this role, can functionally replace ERBB3/HER3 by acting as a more powerful activator of PI3K/AKT signaling. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Lapatinib has clinical efficacy in the treatment of trastuzumab-refractory HER2-positive breast cancer. However, a significant proportion of patients develop progressive disease due to acquired resistance to the drug. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Overexpression of human epidermal growth factor receptor type 3 (HER3) is associated with tumour cell resistance to HER-targeted therapies. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Junctional adhesion molecule-A (JAM-A) is an adhesion molecule whose overexpression on breast tumor tissue has been associated with aggressive cancer phenotypes, including human epidermal growth factor receptor-2 (HER2)-positive disease. Since JAM-A has been described to regulate HER2 expression in breast cancer cells, we hypothesized that JAM-dependent stabilization of HER2 could participate in resistance to HER2-targeted therapies. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: In patients with breast cancer, HER2 gene expression is of a great importance in reacting to Herceptin treatment. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Stromal tumor-infiltrating lymphocytes (sTILs) have been identified as a predictive biomarker for response to neoadjuvant chemotherapy (NAC) and prognosis in human epidermal growth factor receptor 2 (HER2)-positive breast cancers. However, standardized scoring methods for use in clinical practice need to be established, and the optimal threshold of sTILs to predict pathological complete response (pCR) and prognosis in HER2+ breast cancers has not yet been defined. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Estrogen receptor-positive, progesterone receptor-negative, and human epidermal growth factor receptor 2 (HER2)-negative (ER+PR-HER2-) breast cancer comprise a special type of breast cancer that constitutes ~10% of all breast cancer patients. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Recently, HER2-targeted or AR deprivation therapy have been introduced for patients with SDC, therefore, determination of expression profiles of AR and HER2 may be crucial for developing a treatment strategy for patients with metastatic SDC. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Human epidermal growth factor receptor 2 (HER2) inhibitors, such as trastuzumab and lapatinib are used to treat HER2-positive breast and gastric cancers. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The effective treatment of cerebral metastases from HER2-positive breast cancer remains an unmet need. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The BMI greater or equal to 24 (P = .004), number of metastatic lymph nodes greater or equal to 1 (P = .029) and TNM stages I–II (P = .008) were statistically associated with change of HER2 (positive to negative). In patients without pCR, NAC leads to changes in Ki-67, HER2, and hormone receptor (HR) expression. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Predictive utility of tumor-infiltrating lymphocytes (TILs) in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy (NAC) with concurrent trastuzumab remains unclear. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The current study sought to explore the role of YHD on trans-endothelium and angiogenesis of BC. Methods: HER2+ BC cells were treated with YHD, Trastuzumab, or the combination in vitro and in vivo to compare the effects of them on trans-endothelium and angiogenesis features. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso